Search results
Showing 541 to 555 of 720 results for pain management
Outside interests of the NICE board
relief of ischaemic pain. Source guidance details Comes from guidance Peripheral arterial disease: diagnosis and management...
Late-stage assessment (LSA) guidance on intermittent urethral catheters for chronic incomplete bladder emptying in adults.
treated in general wards in hospital and experience significant symptoms of pain and bleeding (haematuria). To explore this research...
Topical antimicrobial dressings for locally infected leg ulcers: late-stage assessment (HTG751)
Late stage assessment (LSA) guidance on topical antimicrobial dressings for locally infected leg ulcers.
View recommendations for HTG751Show all sections
GID-MT567 Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain
In development Reference number: GID-MT567 Expected publication date: TBC
Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA394)
Evidence-based recommendations on evolocumab (Repatha) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.
NICE has developed a medtech innovation briefing (MIB) on 24/7 EEG SubQ for epilepsy .
Peristeen Plus transanal irrigation system for managing bowel dysfunction (HTG462)
Evidence-based recommendations on Peristeen Plus transanal irrigation system for managing bowel dysfunction.
Axumin for functional imaging of prostate cancer recurrence (MIB172)
NICE has developed a medtech innovation briefing (MIB) on Axumin for functional imaging of prostate cancer recurrence .
Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), rituximab (MabThera) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried other disease-modifying antirheumatic drugs (DMARDs) but cannot tolerate them or they have not worked well enough.
Rifaximin for preventing episodes of overt hepatic encephalopathy (TA337)
Evidence-based recommendations on rifaximin (Targaxan) for preventing episodes of hepatic encephalopathy in adults.
Ekso exoskeleton for rehabilitation in people with neurological weakness or paralysis (MIB93)
NICE has developed a medtech innovation briefing (MIB) on the Ekso exoskeleton for rehabilitation in people with neurological weakness or paralysis .
Evidence-based recommendations on ruxolitinib (Jakavi) for polycythaemia vera in adults.
Evidence-based recommendations on autologous chondrocyte implantation in people with symptomatic articular cartilage defects of the knee.